Status:
UNKNOWN
Prevalence of Perimyocarditis After Covid-19 Vaccine
Lead Sponsor:
Hillel Yaffe Medical Center
Conditions:
Perimyocarditis
Covid19
Eligibility:
All Genders
16-60 years
Brief Summary
The aim of this study is to determine whether there is a higher prevalence of perimyocarditis after undergoing vaccination for Covid-19.
Eligibility Criteria
Inclusion
- Patients planning Pfizer-BioNTech BNT162b2 vaccination against Covid19
Exclusion
- Patients infected with Covid19
Key Trial Info
Start Date :
March 9 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2022
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04865900
Start Date
March 9 2021
End Date
April 1 2022
Last Update
April 29 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hillel Yaffe Medical Center
Hadera, Israel, 38100